Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours
NCT01573156Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padeliporfin VTP in renal cell carcinoma (RCC), sponsored by University of Oxford. Primary endpoint: Volume of tumour necrosis on final histology. Started May 2013; status: terminated.
02
Drugs
padeliporfin VTP
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01573156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573156.